Does type of antiretroviral therapy pick-up point influence 12-month virologic suppression in South Africa?

Central Chronic Medicine Dispensing and Distribution Program Differentiated service delivery South Africa community-based care virologic suppression

Journal

AIDS care
ISSN: 1360-0451
Titre abrégé: AIDS Care
Pays: England
ID NLM: 8915313

Informations de publication

Date de publication:
11 Jun 2024
Historique:
medline: 11 6 2024
pubmed: 11 6 2024
entrez: 11 6 2024
Statut: aheadofprint

Résumé

We assessed the impact of community- versus clinic-based medication pick-up on rates of virologic suppression in an observational cohort of adults on ART enrolled in a decentralized antiretroviral therapy program (CCMDD) in South Africa. Participants either attended clinics where they were given the choice to pick up ART in community venues or traditional clinics, or clinics where this pathway was assigned. Among 1856 participants, 977 (53%) opted for community ART pick-up at enrollment, and 1201 (86%) were virologically suppressed at one year. Because of missing data on virologic suppression, primary results are based on a model incorporating multiple imputation. In addition to age and gender, distance from clinic and year of HIV diagnosis were included in the multivariable model. There was no difference in opting for clinic- vs. community-based pick-up with regard to achieving 12-month virologic suppression (aRR 1.02, 95% CI 0.98-1.05) in clinics offering choice. There was no impact of assigning all participants to an external pick-up point (aRR 1.00, 95% CI 0.95-1.06), but virologic suppression was reduced in the clinic that assigned participants to clinic pick-up (aRR 0.87, 95% CI 0.81-0.92). These results suggest that provision of community-based ART has not reduced continued virologic suppression in the population enrolled in the CCMDD program.

Identifiants

pubmed: 38861653
doi: 10.1080/09540121.2024.2361817
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-10

Auteurs

Ingrid V Bassett (IV)

Massachusetts General Hospital, Division of Infectious Diseases, Boston, MA, USA.
Massachusetts General Hospital, Medical Practice Evaluation Center, Boston, MA, USA.
Center for AIDS Research (CFAR), Harvard University, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Africa Health Research Institute, Durban, South Africa.

Joyce Yan (J)

Massachusetts General Hospital, Biostatistics Center, Boston, MA, USA.

Sabina Govere (S)

AIDS Healthcare Foundation, Durban, South Africa.

Anele Khumalo (A)

AIDS Healthcare Foundation, Durban, South Africa.

Zinhle Shazi (Z)

AIDS Healthcare Foundation, Durban, South Africa.

Mpilonhle Nzuza (M)

AIDS Healthcare Foundation, Durban, South Africa.

Taing Aung (T)

Massachusetts General Hospital, Medical Practice Evaluation Center, Boston, MA, USA.

Kashfia Rahman (K)

Massachusetts General Hospital, Medical Practice Evaluation Center, Boston, MA, USA.

Dani Zionts (D)

Massachusetts General Hospital, Medical Practice Evaluation Center, Boston, MA, USA.

Nduduzo Dube (N)

AIDS Healthcare Foundation, Durban, South Africa.

Sandile Tshabalala (S)

South Africa Department of Health, Pietermaritzburg, South Africa.

Laura M Bogart (LM)

RAND Corporation, Santa Monica, CA, USA.

Robert A Parker (RA)

Center for AIDS Research (CFAR), Harvard University, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Massachusetts General Hospital, Biostatistics Center, Boston, MA, USA.

Classifications MeSH